Medications for alcohol, illicit drug, and tobacco dependence: An update of research findings

Journal of Substance Abuse Treatment

Volumn 16, Issue 2, 1999, Pages 105-112

  Litten, Raye Z ^a   Allen, John P ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

Acamprosate; Alcohol dependence; Bupropion; Medication compliance; Naltrexone; Pharmacotherapy

Indexed keywords

ACAMPROSATE; ALCOHOL; AMFEBUTAMONE; BUPRENORPHINE; DISULFIRAM; FLUOXETINE; ILLICIT DRUG; LEVACETYLMETHADOL; METHADONE; NALTREXONE; NICOTINE; NICOTINE GUM; NOSE SPRAY; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ALCOHOLISM; ARTICLE; CLINICAL TRIAL; COCAINE DEPENDENCE; COMORBIDITY; DEPRESSION; DRUG APPROVAL; DRUG DEPENDENCE; FOOD AND DRUG ADMINISTRATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INHALER; INTRANASAL DRUG ADMINISTRATION; METHADONE TREATMENT; OPIATE ADDICTION; PRIORITY JOURNAL; SIDE EFFECT; SUBSTANCE ABUSE; SUBSTITUTION THERAPY; TOBACCO; TRANSDERMAL DRUG ADMINISTRATION; TRANSDERMAL PATCH;

ALCOHOL DETERRENTS; ALCOHOLISM; BUPRENORPHINE; BUPROPION; FORECASTING; HUMANS; METHADYL ACETATE; NALTREXONE; SUBSTANCE-RELATED DISORDERS; TAURINE; TOBACCO USE DISORDER;

EID: 0032900886     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0740-5472(98)00028-2     Document Type: Article

References (57)

1. Allen J.P., Litten R.Z. Techniques to enhance compliance with disulfiram. Alcoholism: Clinical and Experimental Research. 16:1992;1035-1041.
2. Bickel W.K., Stitzer M.L., Bigelow G.W., Liebson K.A., Jasinski D.R., Johnson R.E. A clinical trial of buprenorphine. Comparison with methadone in the detoxification of heroin addicts Clinical Pharmacology and Therapeutics. 43:1988;72-78.
3. Brady K.T., Sonne S.C., Roberts J.M. Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence. Journal of Clinical Psychiatry. 56:1995;502-505.
4. Carroll K., Ziedonis D., O'Malley S., McCance-Katz E., Gordon L., Rounsaville B. Pharmacologic interventions for alcohol- and cocaine-abusing individuals. The American Journal on Addictions. 2:1993;77-79.
5. Chick J., Gough K., Falkowski W., Kershaw P., Hore B., Mehta B., Ritson B., Ropner R., Torley D. Disulfiram treatment of alcoholism. British Journal of Psychiatry. 161:1992;84-89.
6. Cornelius J.R., Salloum I.M., Ehler J.G., Jarrett P.J., Cornelius M.D., Perel J.M., Thase M.E., Black A. Fluoxetine in depressed alcoholics. A double-line placebo-controlled trial Archives of General Psychiatry. 54:1997;700-705.
7. Croop R.S., Faulkner E.B., Labriola D.F. The safety profile of naltrexone in the treatment of alcoholism. Archives of General Psychiatry. 54:1997;1130-1135.
8. Dani J.A., Heinemann S. Molecular and cellular aspects of nicotine abuse. Neuron. 16:1996;905-908.
9. Fuller R.K., Branchey L., Brightwell D.R., Derman R.M., Emrick C.D., Iber F.L., James K.E., Lacourseire R.B., Lee K.K., Lowstam I., Maany I., Neiderhiser D., Nocks J.J., Shaw S. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study Journal of the American Medical Association. 256:1986;1449-1455.
10. Geerlings P.J., Ansoms C., van den Brink W. Acamprosate and prevention of relapse in alcoholics. European Addiction Research. 3:1997;129-137.
11. Gerra G., Caccavari R., Delsignore R., Bocchi R., Fertonani G., Passeri M. Effects of fluoxetine and Ca-acetyl-homotaurinate on alcohol intake in familial and nonfamilial alcoholics patients. Current Therapeutic Research. 52:1992;291-295.
12. Giros B., Jaber M., Jones S.R., Wightman R.M., Caron M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 379:1996;606-612.
13. Glaxo Wellcome Use of bupropion hydrochloride in smoking cessation therapy. 1997;Author, Research Triangle Park, NC.
14. Herman B.H., Vocci F., Bridge P. The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development issues for opiate addiction Neuropsychopharmacology. 13:1995;269-293.
15. Herman, B.H., Vocci, F., Bridge, P., & Litten, R.Z. (1996). Medications development for opiate, cocaine, and alcohol dependence. Paper presented for American Academy of Child and Adolescent Psychiatry, Philadelphia, PA.
16. Higgins S.T., Budney A.J., Bickel W.K., Hughes J.R., Foerg F. Disulfiram therapy in patients abusing cocaine and alcohol. American Journal of Psychiatry. 150:1993;675-676.
17. Hughes J.R., Gust S.W., Keenan R.M., Fenwick J.W., Healey M.L. Nicotine vs placebo gum in general medical practice. Journal of American Medical Association. 261:1989;1300-1305.
18. Hughes J.R., Gust S.W., Keenan R., Fenwick J.W., Skoog K., Higgins S.T. Long-term use of nicotine vs placebo gum. Archives of Internal Medicine. 151:1991;1991-1998.
19. Hurt R.D., Glover E.D., Sachs D.P.L., Dale L.C., Schroeder D.R. Bupropion for smoking cessation. A double-blind, placebo-controlled dose response trial Journal of Addictive Diseases. 15:1996;137.
20. Jaffe J.H. Pharmacological treatment of opioid dependence. Current techniques and new findings Psychiatric Annals. 25:1995;369-375.
21. Julius D. Another opiate for the masses? Nature. 386:1997;442.
22. Johnson R.E., Jaffe J.H., Fudala P.J. A controlled trial of buprenorphine treatment for opioid dependence. Journal of the American Medical Association. 267:1992;2750-2755.
23. Keenan R.M., Jarvik M.E., Henningfield J.E. Management of nicotine dependence and withdrawal. Miller N.S. Principles of addiction medicine. 1994;1-11 American Society of Addiction Medicine, Chevy Chase, MD. Section XI, Chapter 7
24. Leshner A.I. Molecular mechanisms of cocaine. The New England Journal of Medicine. 335:1996;128-129.
25. Lhuintre J.P., Daoust M., Moore N.D., Chretien P., Saligaut C., Tran G., Boismare F., Hillemand B. Ability of calcium acetyl homotaurine, A GABA agonist, to prevent relapse in weaned alcoholics. The Lancet. 1:1985;1014-1016.
26. Lhuintre J.P., Moore N., Tran G., Steru L., Langrenon S., Daoust M., Parot Ph., Ladure Ph., Libert C., Boismare F., Hillemand B. Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol and Alcoholism. 25:1990;613-622.
27. Litten R.Z., Allen J.P., Gorelick D.A., Preston K. Experimental pharmacological agents to reduce alcohol, cocaine, and opiate use. Miller N.S. The principles and practice of addictions in psychiatry. 1997;532-567 W.B. Saunders Company, Philadelphia, PA.
28. Litten R.Z., Fertig J. International update. New findings on promising medications Alcoholism: Clinical and Experimental Research. November(suppl.)):1996;216A-218A.
29. Mann, K., Chabac, S., Lehert, P., Potgieter, A., & Sass, H. (1995). Acamprosate improves treatment outcome in alcoholics: A polled analysis of 11 randomized placebo controlled trials in 3338 patients. Poster presented at the Annual Conference of the American College of Neuropsychopharmacology, Puerto Rico.
30. Mason B.J., Kocsis J.H., Ritvo E.C., Cutler R.B. A double-blind placebo-controlled trial of desipramine in primary alcoholics stratified on the presence or absence of major depression. Journal of the American Medical Association. 275:1996;1-7.
31. McGrath P.J., Nunes E.V., Stewart J.W., Goldman D., Agosti V., Ocepek-Welikson K., Quitkin F.M. Imipramine treatment of alcoholics with primary depression. A placebo-controlled clinical trial Archives of General Psychiatry. 53:1996;232-240.
32. Meandzija B., Kosten T.R. Pharmacologic therapies for opioid addiction. Miller N.S. Principles of addiction medicine. 1994;1-5 American Society of Addiction Medicine, Chevy Chase, MD. Section XII, Chapter 4
33. Mello N.K., Mendelson J.H. Buprenorphine suppresses heroin use by heroin addicts. Science. 207:1980;657-659.
34. Mello N.K., Mendelson J.H., Kuehnle J.C. Buprenorphine effects on human heroin self-administration. An operant analysis The Journal of Pharmacology and Experimental Therapeutics. 223:1982;30-39.
35. Mendelson J.H., Mello N.K. Management of cocaine abuse and dependence. The New England Journal of Medicine. 334:1996;965-972.
36. National Institute on Drug Abuse. (1996). Cigarette smoking. In NIDA Capsules (Report No. C-83-08, January Issue). Rockville, MD: Press Office of the National Institute on Drug Abuse.
37. O'Brien C.P., McLellan A.T. Myths about the treatment of addiction. The Lancet. 347:1996;237-240.
38. O'Malley S.S., Jaffe A.J., Chang G., Schottenfield R.S., Meyer R.E., Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study Archives of General Psychiatry. 49:1992;881-887.
39. Paille F.M., Guelfi J.D., Perkins A.C., Royer R.J., Steru L., Parot P. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol and Alcoholism. 30:1995;239-247.
40. Robinson G.M., Dukes P.D., Robinson B.J., Cooke R.R., Mahoney G.N. The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington, New Zealand. Drug and Alcohol Dependence. 33:1993;81-86.
41. Rocio M., Carrera A., Ashley J.A., Parsons L.H., Wirsching P., Koob G.F., Janda K.D. Suppression of psychoactive effects of cocaine by active immunization. Nature. 378:1995;727-730.
42. Rose J.E., Behm F.M., Westman E.C., Levin E.D., Stein R.M., Ripka G.V. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clinical Pharmacology and Therapeutics. 56:1994;86-99.
43. Rose J.E., Levin E.D., Behm F.M., Adivi C., Schur C. Transdermal nicotine facilitates smoking cessation. Clinical Pharmacology and Therapeutics. 47:1990;323-330.
44. Rustin T.A. Pharmacologic therapies for nicotine addiction. Miller N.S. Principles of addiction medicine. 1994;1-8 American Society of Addiction Medicine, Chevy Chase, MD. Section XII, Chapter 5
45. Sass H., Soyka M., Mann K., Zieglgansberger W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence Archives of General Psychiatry. 53:1996;673-680.
46. Schneider N.G., Lunell E., Olmstead R.E., Fagerstrom K.O. Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems Clinical Pharmacokinetics. 31:1996;65-80.
47. Schneider N.G., Olmstead R., Nisson F., Mody F.V., Franzon M., Doan K. Efficacy of a nicotine inhaler in smoking cessation. A double-blind, placebo-controlled trial Addiction. 91:1996;1293-1306.
48. 2-like dopamine receptor agonists. Science. 271:1996;1586-1589.
49. Spanagel R., Zieglgansberger W. Anti-craving compounds for ethanol. New pharmacological tools to study addictive processes Trends in Pharmacological Sciences. 18:1997;54-59.
50. Strain E.C., Stitzer M.L., Liebson I.A., Bigelow G.E. Comparison of buprenorphine and methadone in the treatment of opioid dependence. American Journal of Psychiatry. 151:1994;1025-1030.
51. Transdermal Nicotine Study Group Transdermal nicotine for smoking cessation. Six-month results from two multicenter controlled clinical trials Journal of American Medical Association. 266:1991;3133-3138.
52. Volkow N.D., Wang G.J., Fischman M.W., Foltin R.W., Fowler J.S., Abumrad N.N., Vitkun S., Logan J., Gatlery S.J., Pappas N., Hitzemann R., Shea C.E. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature. 386:1997;827-830.
53. Volpicelli J.R., Alterman A.I., Hayashida M., O'Brien C.P. Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry. 49:1992;876-880.
54. Volpicelli J.R., Rhines K.C., Rhines J.S., Volpicelli L.A., Alterman A.I., O'Brien C.P. Naltrexone and alcohol dependence. Role of subject compliance Archives of General Psychiatry. 54:1997;737-742.
55. Weinhold L.L., Preston K.L., Farre M., Liebson I.A., Bigelow G.E. Buprenorphine alone and in combination with naloxone in non-dependent humans. Drug and Alcohol Dependence. 30:1992;263-274.
56. Whitworth A.B., Fischer F., Lesch O.M., Nimmerrichter A., Oberbauer H., Platz T., Potgieter A., Walter H., Fleischhacker W.W. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. The Lancet. 347:1996;1438-1442.
57. Zadina J.E., Hackler L., Ge L.J., Kastin A.J. A potent and selective endogenous agonist for the μ-opiate receptor. Nature. 386:1997;499-502.